What does ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES do?

ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”. Also registered: wholesaler, repair and maintenance company. Public Limited, started on 22 March 2007, 1 establishment.

What is the address of ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES?

The registered office of ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES is located at Rue Emile Francqui 3, 1435 Mont-Saint-Guibert.

Is ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES still active?

Yes. According to the CBE (29 October 2026) ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES is active, legal situation “Normale toestand”, started on 22 March 2007.

Is ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES registered on Peppol?

Yes, ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES is registered on the Peppol network with ID 0208:0888210786.

What is the enterprise number of ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES?

The enterprise number of ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES is BE0888210786.

When was ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES founded?

ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES was founded on 22 March 2007.

Who are the directors of ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES?

According to the 2025 annual accounts, the directors of ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES are: Benoit LESSIRE, Sebastien DELPORTE.

Is ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 March 2007; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES make in 2025?

ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES posted a profit after taxes of € 13,904,566 in financial year 2025.

What is the revenue of ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES?

In its most recent annual accounts (2025), ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES reported revenue of € 270,436,467.

How much does an employee at ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES earn?

The average wage cost per full-time employee at ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES was € 216,500 in 2025: staff costs of € 7.1 million for 32.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES have?

According to the 2025 annual accounts, ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES has 32.8 full-time equivalents (FTE).

ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES (Public Limited)

Dossier ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES, printed on 29 October 2026 from databakkes.be/en/0888210786/eli-lilly-european-clinical-trial-services. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES from Mont-Saint-Guibert, company number BE0888210786, closed financial year 2025 with a result of € 13.9 million after tax. For that financial year ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES recorded revenue of € 270.4 million and equity of € 5 million. Compared with financial year 2024, the result moved from € 13.5 million to € 13.9 million. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.

What it is worth Healthy

€ 5 million

▼ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 13.9 million

▲ 3% vs 2024

Profit after tax over the fiscal year.

Where the profit goes Pays out

€ 14 million paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

32.8

▲ 0.4 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 246.7 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 7.1 million

▲ 14% vs 2024

€ 216,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 234,217

▼ 2% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 36.6 million

▼ 5% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 54 days on average.

Wages and social charges

€ 1.7 million

▲ 10% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2024	2025	Change 2024 → 2025
Revenue	€ 185,720,704 Revenue 2021: € 185,720,704 First fiscal year in the series	€ 233,502,447 Revenue 2022: € 233,502,447 ▲ 26% vs 2021 (€ 185,720,704) Favourable step	€ 279,426,012 Revenue 2024: € 279,426,012 ▲ 20% vs 2022 (€ 233,502,447) Favourable step	€ 270,436,467 Revenue 2025: € 270,436,467 ▼ 3% vs 2024 (€ 279,426,012) Unfavourable step	▼ 3%
Profit after taxes	€ 9,079,702 Profit after taxes 2021: € 9,079,702 First fiscal year in the series	€ 11,361,275 Profit after taxes 2022: € 11,361,275 ▲ 25% vs 2021 (€ 9,079,702) Favourable step	€ 13,470,001 Profit after taxes 2024: € 13,470,001 ▲ 19% vs 2022 (€ 11,361,275) Favourable step	€ 13,904,566 Profit after taxes 2025: € 13,904,566 ▲ 3% vs 2024 (€ 13,470,001) Favourable step	▲ 3%
Equity	€ 13,892,644 Equity 2021: € 13,892,644 First fiscal year in the series	€ 5,253,919 Equity 2022: € 5,253,919 ▼ 62% vs 2021 (€ 13,892,644) Unfavourable step	€ 5,051,134 Equity 2024: € 5,051,134 ▼ 4% vs 2022 (€ 5,253,919) Unfavourable step	€ 4,955,701 Equity 2025: € 4,955,701 ▼ 2% vs 2024 (€ 5,051,134) Unfavourable step	▼ 2%
Total debts	€ 27,749,474 Total debts 2021: € 27,749,474 First fiscal year in the series	€ 50,824,817 Total debts 2022: € 50,824,817 ▲ 83% vs 2021 (€ 27,749,474) Unfavourable step	€ 53,720,042 Total debts 2024: € 53,720,042 ▲ 6% vs 2022 (€ 50,824,817) Unfavourable step	€ 52,450,781 Total debts 2025: € 52,450,781 ▼ 2% vs 2024 (€ 53,720,042) Favourable step	▼ 2%
Land & buildings	€ 46,483 Land & buildings 2021: € 46,483 First fiscal year in the series	€ 58,654 Land & buildings 2022: € 58,654 ▲ 26% vs 2021 (€ 46,483) Unchanged	-	-
Retained profit	€ 9,592,644 Retained profit 2021: € 9,592,644 First fiscal year in the series	€ 953,919 Retained profit 2022: € 953,919 ▼ 90% vs 2021 (€ 9,592,644) Unfavourable step	€ 751,134 Retained profit 2024: € 751,134 ▼ 21% vs 2022 (€ 953,919) Unfavourable step	€ 655,701 Retained profit 2025: € 655,701 ▼ 13% vs 2024 (€ 751,134) Unfavourable step	▼ 13%
Dividend	€ 0 Dividend 2021: € 0 First fiscal year in the series	€ 20,000,000 Dividend 2022: € 20,000,000 Unchanged (€ 0) Unchanged	€ 13,500,000 Dividend 2024: € 13,500,000 ▼ 32% vs 2022 (€ 20,000,000) Unchanged	€ 14,000,000 Dividend 2025: € 14,000,000 ▲ 4% vs 2024 (€ 13,500,000) Unchanged	▲ 4%
Balance sheet total	€ 41,642,117 Balance sheet total 2021: € 41,642,117 First fiscal year in the series	€ 56,078,736 Balance sheet total 2022: € 56,078,736 ▲ 35% vs 2021 (€ 41,642,117) Unchanged	€ 58,771,176 Balance sheet total 2024: € 58,771,176 ▲ 5% vs 2022 (€ 56,078,736) Unchanged	€ 57,406,482 Balance sheet total 2025: € 57,406,482 ▼ 2% vs 2024 (€ 58,771,176) Unchanged	▼ 2%
Employees (FTE)	31.8 Employees (FTE) 2021: 31.8 First fiscal year in the series	31.5 Employees (FTE) 2022: 31.5 ▼ 0.3 vs 2021 (31.8) Unchanged	32.4 Employees (FTE) 2024: 32.4 ▲ 0.9 vs 2022 (31.5) Unchanged	32.8 Employees (FTE) 2025: 32.8 ▲ 0.4 vs 2024 (32.4) Unchanged	▲ 0.4

Key figures of ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES?

What happened at ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 22, 2026 New annual accounts for financial year 2025: profit of € 13.9 million (▲ 3% vs 2024). Source: NBB ↗
2026 Benoit LESSIRE stepped down as director. NBB
2026 Sebastien DELPORTE stepped down as director. NBB
2019 Benoit LESSIRE became a director. NBB
2019 Sebastien DELPORTE became a director. NBB
Mar 22, 2007 New establishment in Mont-Saint-Guibert. KBO
Mar 22, 2007 Start of the company according to the CBE. KBO

In short

From € 9.1 million profit in 2021 to € 13.9 million profit in 2025.

Paid € 16 million in corporate taxes since 2021.

Best year ever: 2025, with € 13.9 million profit.

Paid out € 47.5 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

ELI LILLY NETHERLAND BV 100%

ELI LILLY BENELUX SA 0%

ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES

The shares are held by ELI LILLY NETHERLAND BV (100%) and ELI LILLY BENELUX SA (0%).

Directors

According to the 2025 annual accounts

Benoit LESSIRE

Chairman of the board

since 2019 · until 2026

Sebastien DELPORTE

Director

Also active at: TriBE Concept

since 2019 · until 2026

Shareholders

ELI LILLY NETHERLAND BV

100%

ELI LILLY BENELUX SA

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Emile Francqui 3

1435 Mont-Saint-Guibert

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

OpenWAY Europe

€ 29.6 million revenue · 2025

BALENCIO

€ 800,087 gross margin · 2025

Metronom Health Europe

€ 3.1 million gross margin · 2024

EverFlourish Belgium

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0888.210.786

VAT number

BE 0888.210.786

Registered office

Rue Emile Francqui 3, 1435 Mont-Saint-Guibert

Names & denominations

ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

22 March 2007

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Overige zakelijke dienstverlening, n.e.g.

Overige zakelijke dienstverlening, neg

Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden

Vervaardiging van elektrische apparaten voor de geneeskunde, de tandheelkunde en de veeartsenijkunde

Groothandel in chemische producten voor industrieel gebruik

Groothandel in farmaceutische en medische artikelen

Vervaardiging van orthopedische artikelen en prothesen

Groothandel in chemische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES

Financials

What happened to ELI LILLY EUROPEAN CLINICAL TRIAL SERVICES?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions